Open AccessP1100: BRUIN MCL‐321: A PHASE 3 OPEN‐LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED, BTK INHIBITOR NAÏVE MCL (TRIAL IN PROGRESS)
Author(s) -
Eyre T. A.,
Shah N. N.,
Le Gouill S.,
Dreyling M.,
Vandenberghe E.,
Jurczak W.,
Wang Y.,
Cheah C. Y.,
Gandhi M.,
Chay C.,
Sharman J. P.,
Andorsky D. J.,
Yin M.,
Balbas M.,
Kherani J.,
Wang M. L.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847268.67095.fc
Subject(s) - ibrutinib , bruton's tyrosine kinase , mantle cell lymphoma , chemistry , pharmacology , medicine , chronic lymphocytic leukemia , tyrosine kinase , leukemia , lymphoma , receptor